Verve Therapeutics (NASDAQ:VERV) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Verve Therapeutics (NASDAQ:VERV) from a sell rating to a hold rating in a research report report published on Thursday morning.

A number of other brokerages have also recently issued reports on VERV. Canaccord Genuity Group upped their price objective on Verve Therapeutics from $32.00 to $39.00 and gave the stock a “buy” rating in a research note on Tuesday, April 15th. Royal Bank of Canada dropped their price objective on Verve Therapeutics from $17.00 to $15.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 4th. HC Wainwright boosted their target price on Verve Therapeutics from $15.00 to $25.00 and gave the stock a “buy” rating in a report on Monday, April 14th. William Blair reissued an “outperform” rating on shares of Verve Therapeutics in a report on Friday, February 21st. Finally, Guggenheim boosted their target price on Verve Therapeutics from $18.00 to $24.00 and gave the stock a “buy” rating in a report on Tuesday, April 15th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $25.75.

Verve Therapeutics Stock Up 3.5%

Shares of Verve Therapeutics stock opened at $4.38 on Thursday. Verve Therapeutics has a 12-month low of $2.86 and a 12-month high of $9.31. The stock has a market cap of $390.45 million, a P/E ratio of -1.78 and a beta of 1.82. The business’s 50 day moving average is $4.64 and its 200-day moving average is $5.82.

Verve Therapeutics (NASDAQ:VERV) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.36. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. The company had revenue of $32.98 million for the quarter, compared to analysts’ expectations of $7.13 million. On average, sell-side analysts expect that Verve Therapeutics will post -2.49 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in VERV. Nisa Investment Advisors LLC increased its holdings in shares of Verve Therapeutics by 465.4% during the 4th quarter. Nisa Investment Advisors LLC now owns 42,781 shares of the company’s stock worth $241,000 after acquiring an additional 35,214 shares during the last quarter. Impact Partnership Wealth LLC acquired a new position in Verve Therapeutics in the 4th quarter valued at $70,000. China Universal Asset Management Co. Ltd. grew its holdings in Verve Therapeutics by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 17,952 shares of the company’s stock valued at $101,000 after buying an additional 1,676 shares in the last quarter. Rhumbline Advisers grew its holdings in Verve Therapeutics by 1.9% in the 4th quarter. Rhumbline Advisers now owns 111,203 shares of the company’s stock valued at $627,000 after buying an additional 2,093 shares in the last quarter. Finally, IFP Advisors Inc grew its holdings in Verve Therapeutics by 823,700.0% in the 4th quarter. IFP Advisors Inc now owns 8,238 shares of the company’s stock valued at $47,000 after buying an additional 8,237 shares in the last quarter. 97.11% of the stock is owned by institutional investors and hedge funds.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.